News
FDA will increase postmarketing surveillance of drugs
BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7476.1203-a (Published 18 November 2004) Cite this as: BMJ 2004;329:1203- Janice Hopkins Tanne
- New York
After controversies about the possible increased risk of suicide in children taking antidepressants and the increase in heart attacks and strokes in patients taking rofecoxib (Vioxx, MSD), the US Food and Drug Administration has announced plans to strengthen its surveillance of drugs on the market.
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.